A tanning peptide; approved only as an implant for a rare disease.
iNot medical advice. We don’t recommend any dose. Every dose below is a quote from the person named, describing their views or their own use. Afamelanotide (Scenesse) is approved in the EU and US only as a doctor-inserted implant for erythropoietic protoporphyria. Melanotan 1 sold online for injection is an unlicensed research chemical.
2 statements from 2 people. Each one is word for word: we add punctuation only and mark cuts with […]. The chips repeat the exact words used.
“HOW I USE MELANOTAN 1: 500 mcg injected subcutaneously 3 times a week, with the doses evenly spaced out within the week.”
Context: Own use, from an article listing “the peptides I am using nearly every day”. He says he takes it for a calm state of mind rather than for tanning, and that he no longer uses Melanotan 2.
“Melanotan-1: 500 mcg injected subcutaneously three times a week, with the doses evenly spaced out within the week.”
Context: From a list of stacks he says he recommends. Just before the list he writes that he has discussed his favourite stacks “with Jay Campbell” and does not want to reinvent the wheel; the wording matches Jay Campbell’s 2022 own-use article almost exactly, so this is best read as Greenfield endorsing the same protocol rather than as a separate one.
0 statements from 0 people about risks and how strong the evidence is.
No expert safety statements are listed yet.
Context, not a dosing guide. The trials below tested a 16 mg implant every 60 days in people with a rare skin disease, not injections in healthy people. They do not tell you a dose for tanning or other uses.
| Study | Studied in | What the study used | What it found |
|---|---|---|---|
| Langendonk et al., 2015, N Engl J MedPubMed 26132941 | 168 people with erythropoietic protoporphyria (EU and US trials) | 16 mg afamelanotide implant under the skin every 60 days vs placebo | More pain-free time in sunlight and better quality of life; side effects mostly mild |
No. Melanotan 1 (afamelanotide) acts mainly on the pigment receptor; Melanotan 2 also acts on receptors involved in appetite and arousal.
Ben Greenfield’s 2023 list repeats, almost word for word, the protocol Jay Campbell published in 2022 as his own use. We show both and say so on the card.
We do not write our own dose ranges. The protocol cards show, word for word, what named people have publicly said, with their caveats and a link to the source.
Word-for-word statements about how Melanotan 1 (MT-1) is used, each with a link to the source. Its approved form, afamelanotide, is an implant for a rare light-sensitivity disease; the injectable research peptide is a different product. The research is listed separately as context.
Last reviewed 11 Oct 2026 · Compiled by the Peptide Dosing editorial team · How we check quotes